Today it was reported that the President & CEO of Cryolife (NYSE: CRY), James Mackin, exercised options to sell 150,000 CRY shares at $10.24 a share, for a total transaction value of $4.82M.
In addition to James Mackin, 7 other CRY executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $68.5 million and quarterly net profit of $224K. In comparison, last year the company earned revenue of $47.82 million and had a net profit of $3.1 million. Currently, Cryolife has an average volume of 133.1K.
The insider sentiment on Cryolife has been negative according to 89 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
